This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Aratana Therapeutics Drives Awareness Of Pet Therapeutic Opportunity During "CVC Week" In Kansas City

KANSAS CITY, Kan., Sept. 3, 2013 /PRNewswire/ --  Aratana Therapeutics (Nasdaq: PETX), a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets (pet therapeutics), participated in several business development and leadership events during "CVC Week" in Kansas City.   The Conference for Veterinary Care (CVC) and adjunctive events, including the 2013 Animal Health Research Symposium and the Animal Health Early+Mid-Stage Investment Forum, were organized from August 23-27, 2013 to advance the growth and science of veterinary and animal care.

Showcasing its leadership position in the development and commercialization of innovative medications for pets, Aratana's Head of Drug Evaluation and Development, Ernst Heinen, DVM, Ph.D., delivered a presentation during the 2013 Animal Health Research Symposium entitled, "From Human Research To Pet Therapeutics."  Dr. Heinen's presentation highlighted the need for improved medications for dogs and cats, and the greenfield opportunity to develop drugs presently for human applications into therapeutics specifically for use in pets.

Separately, Aratana's Chief Scientific Officer, Linda Rhodes, VMD, Ph.D., a pioneer in the veterinary and animal health industry, presented the "2013 Innovation Award" at the Animal Health Early+Mid-Stage Investment Forum.   Sponsored by Aratana, the Innovation Award recognizes a single company that combines the most promising scientific and business opportunity. 

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, stated, "CVC Week is one of the significant annual events in animal health and veterinary care, and since we are a Kansas City-headquartered company, we are particularly pleased to play a leadership role in the emerging pet therapeutics space."

About Aratana TherapeuticsAratana Therapeutics is a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit  www.aratana.com.

Contacts: Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D. (investors) jdrumm@tiberend.com ; (212) 375-2664

Andrew Mielach (media) amielach@tiberend.com ; (212) 375-2694

SOURCE Aratana Therapeutics

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,601.97 -81.61 -0.46%
S&P 500 2,064.47 -4.29 -0.21%
NASDAQ 4,969.7230 -22.2170 -0.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs